Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19.
Tags: ACE, ACUTE RESPIRATORY DISTRESS SYNDROME, ALTERNATIVE, C5, COMPLEMENT ACTIVATION, COMPLEMENT C3, COMPLEMENT PATHWAY, COVID-19, ECULIZUMAB, GLOMERULAR FILTRATION RATE, GRAFT SURVIVAL, HEMOGLOBIN, HEMOLYSIS, IL6, IMMUNITY, PLATELET COUNT, SARS-COV-2